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INTRODUCTION 
Hypertransaminasemia, increased serum transaminases, is a re-
cognized side-effect of heparin."'" The potential clinical signifi-
2 
cance and mechanism of this side-effect remains to be determined. 
Hypertransaminasemia associated with heparin has not been reported to 
produce clinical illness; however, the determination of transaminase 
3 
levels is an established diagnostic aid for pulmonary embolism, 4 5 hepatic damage and myocardial infarction which could be misdiagnosed 
in the presence of heparin administration. Likewise, transaminase 
* 
levels can be valuable prognostic and monitoring aids in certain 
6 7 
rheumatic diseases, ' which may be lost in the patients receiving 
heparin. 
In their original observation of this phenomenon, Sonnenblick 
et al^ noted a transient rise in patients' serum transaminase values 
during a course of full-dose heparin therapy. This prospective study 
demonstrated that 10 of 14 patients had elevated serum glutamic 
pyruvic transaminase (SGPT) and serum glutamic oxaloacetic trans-
aminase (SGOT) levels during a regimen of therapeutic heparinization, 
and return to normal values with cessation of therapy. Maximum 
transaminase elevations were 3 to 5 times normal values and were not 
associated with subjective symptoms. Levels of SGPT were higher than 
those of SGOT, suggesting a hepatic origin for the hypertrans-
aminasemia.^ 
Two other reports in the literature also describe this 
9,10 
phenomenon. In these patients, the description of the rise in 
serum transaminases is essentially the same as reported by Sonnenblick 
et al."'" The major exception was the observation that the elevated 
enzymes began to decrease even with continued heparin administration. 
In a recent study designed to evaluate the incidence of thrombo-
cytopenia due to low-dose heparin, Saffle et al^ also noted that 
subjects experienced elevations of the serum enzymes SGPT, SGOT and 
LDH. They found that 62 percent (21 of 34) of their subjects ex-
perienced elevation of these enzymes, above normal limits, by day 10 
of therapy. The enzyme pattern demonstrated by their subjects was 
f 
typical of hepatocellular damage, SGPT values exceeded SGOT and were 
paralleled by a smaller but significant rise in lactic dehydrogenase 
g 
(LDH). In all cases the levels returned to normal within 14 days 
of discontinuing heparin therapy. 
Commercial heparin products are derived primarily from beef lung 
and pork intestinal mucosa. Although there are chemical and biologi-
12 
cal differences between heparin derived from these sources there is 
only limited evidence to suggest that there are any clinical dif-
ferences . ^ ' ' ^  In the investigation of low-dose heparin therapy"'""'" 
the incidence of increased serum enzymes was significantly higher in 
the subjects receiving pork mucosal heparin (93 percent) than those 
receiving beef lung heparin (37 percent) (P <0.05, chi-square). To 
date this has been the only report identifying a difference in the 
incidence of increased serum enzymes with the different heparin 
preparations. 
3 
The objectives of this study were threefold: To determine the 
incidence of elevated serum enzyme (SGPT, SGOT and LDH) levels at-
tributable to the administration of heparin to adult medical and surgi-
cal patients; to characterize the observed onset, duration and course 
of the heparin induced rise in serum enzymes; and, to delineate dif-
ferences between pork intestinal and beef lung mucosal heparin in the 
frequency or extent of the induced rise in serum enzymes. 
This report is a preliminary account of the data that have been 
collected. Readers are advised that'additional patients were being 
added to the study at the time of this writing. 
MATERIALS AND METHODS 
Study Design and Randomization 
The study was conducted in a prospective, randomized, open 
noncrossover design. Randomization was achieved by consecutive as-
signment of patients to beef or pork heparin according to a pre-
determined random sequence. The sequence was generated from odd/even 
analysis of the terminal digit in a random number table. ^  
Patients Eligibility 
All patients admitted to the University of Utah Hospital and the 
Salt Lake Veterans Administration Medical Center who were to receive 
therapeutic heparinization for a minimum of four days were eligible 
for this study. Eligibility was based on acceptable entry parameters 
for a physical examination, medical and drug histories and the fol-
lowing background laboratory studies: Complete blood count (CBC) 
with differential; urinalysis; and serum sodium, potassium, chloride, 
4 
carbon dioxide (CO,,) , blood urea nitrogen (BUN), glucose, total and 
indirect bilirubin, LDH, SGPT, SGOT, alkaline phosphatase, uric acid, 
cholesterol, total protein, albumin, calcium, phosphorus, creatinine 
and gamma glutamyl transpeptidase (GGTP). Partial thromboplastin 
time (PTT), prothrombin time (PT), and platelet count were also per-
formed as baseline determinations. 
Patient Exclusions * " 
Patients were excluded from this study if they had a history of 
documented coagulopathy or platelet disorder, if an abnormality was 
demonstrated in the platelet count, PT, PTT or if they had a history 
of abnormal bleeding or heparin allergy. Patients who had cardio-
* 
pulmonary bypass surgery or hemodialysis within the previous seven 
days were excluded. Patients with elevations of serum enzymes (i.e., 
above normal limits established by the clinical laboratories - see 
Tables 1, 2 and 3) were admitted to the study on an individual basis 
according to the discretion of the investigators. No patients with 
frank hepatic damage (i.e., markedly elevated transaminases, jaun-
dice, hepatomegaly, etc.) were admitted to the study. Patients with 
carcinoma or a past history of deep vein thrombosis or other vascular 
diseases were not excluded from the study, but the history was re-
corded. Patients with a positive history of anticoagulant or aspirin 
use prior to admission were not excluded if their hemostatic para-
meters were normal. 
Procedure 
Entry and initial evaluation: Upon identification of patients 
who met basic study requirements, house officers contacted one of the 
investigators. After attaining informed written consent an "Initial 
Report Form" was completed which showed the patient's name, date, 
diagnosis, associated diagnoses, positive history and physical find-
ings, positive laboratory and X-ray findings, and past and present 
medications. 
Drugs and administration: Patients entered into the study re-
ceived pork intestinal heparin (sodium salt, 10,000 units/ml, Elkins-
Sinn, Inc., Lot # 051035) or beef lung heparin (sodium salt, 10,000 
units/ml, Upjohn, Inc., Lot # 195283} according to the predetermined 
sequence. The drugs were administered by continuous intravenous in-
fusion, utilizing an infusion pump. Monitoring of anticoagulation, 
by usual laboratory and clinical methods, was the responsibility of 
the patient's primary physician. 
Laboratory studies: The clinical laboratories at the University 
and Veterans Hospitals performed the laboratory determinations on 
study patients at the respective hospitals. Platelet counts were 
performed on an automated Coulter Counter; any counts less than 3 
50,000/mm were verified with a hemocytometer. Serum chemistries 
were performed on automated machinery. Serum clotting studies were 
done in the clinical coagulation laboratory. 
Schedule of laboratory studies: Within 24 hours of the initi-
ation of heparin therapy, the following laboratory tests were 
performed: 
a. CBC with differential 
b. Quantitative platelet count 
c. Serum chemistry profile 
1. Sodium 11. Calcium 
2. Potassium 12. Phosphorus 
3. Chloride 13. Total protein 
4. co2 14. Albumin 
5. BUN 15. Cholesterol 
6. Glucose 16. Alkaline phosphatase 
7. Total bilirubin 17. SGPT 
8. Direct bilirubin " 18. SGOT 
9. Creatinine - 19. LDH 
10. Uric acid 20. GGTP 
A serum chemistry profile, which included the enzymes SGPT, 
and LDH, was obtained every other day during heparin therapy, i.e., 
days 2, 4, 6, 8 etc. Where possible, patients who experienced ele-
vation of any of these enzymes above laboratory normals had daily 
values obtained until they returned to normal. Any other abnormal 
values on the chemistry profile were also monitored, where possible, 
until they had returned to normal. 
Quantitative platelet counts were performed every other day 
during heparin therapy, i.e., days 2, 4, 6, 8 etc. In all patients 
3 
whose platelet count was less than 100,000/mm , daily platelet counts 
were performed, where possible, until they had returned to normal. 
Daily investigator monitoring: The status of the initial throm-
boembolic condition and any new evidence of intravascular thrombosis 
was noted daily. In all patients who developed a rise in any of the 
serum enzymes, a "Concomitant Therapy" form was completed so that all 
other medications taken prior to and during its occurrence were 
recorded. 
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Conditions for premature discontinuation of therapy: Heparin 
therapy was discontinued, at the discretion of the patient's primary 
physician, if clinically significant bleeding occurred. Protamine was 
administered at his discretion, according to the requirements of the 
clinical situation. If significant and/or persistent thrombocytopenia 
3 (platelets less than 50,000/mm on one occasion or platelets less than 
3 
100,000/mm for three consecutive days) occurred, and it was thought 
that heparin was contributing to it, the heparin therapy was discon-
tinued. If in the opinion of the primary physician, SGPT, SGOT or 
LDH were elevated to such a degree as to be of potential permanent 
danger to the patient, and if heparin was thought to be contributing 
to the cause of this elevation, the heparin was discontinued. 
Statistical Methods 
The statistical significance of the differences between both 
paired or independent samples was determined using the t-test of 
correlated or independent means respectively. Pearson's Correlation 
Coefficients were determined using a conventional method for calcu-
lating this statistic.^ In evaluating the significance of baseline 
values of SGPT, SGOT or LDH in relation to the extent of rise of 
these enzymes, the Mantel-Haenszel test was utilized.^ For compari-
son of the influence of heparin type on incidence of abnormally high 
peaks of SGOT, SGPT or LDH, Fisher's Exact Test was employed.1' 
Study Definitions 
Four working definitions were utilized in evaluating the results 
of the study. For the purpose of evaluating the effects of heparin, 
any rise greater than 10 percent over baseline for LDH or 20 percent 
over baseline for either SGPT or SGOT was included. Rises of this 
magnitude would be beyond the normal variation for these tests as per-
formed by the clinical laboratories (see Table 1, 2 and 3). Only 
those values which were obtain while the patient was on heparin are 
considered in the evaluation. Though the occasional patient did con-
tinue to have increasing enzymes after heparin was discontinued, data 
could not be collected regularly enough to justify including these 
values. Increases for any of the enzymes were utilized in the analy-
sis as ratio (peak/baseline) increases as opposed to unit increases. 
Actual units increased were utilized only as contrasts or descriptive 
statistics. Statistical evaluation included only those patients who 
exhibited a rise in enzymes above baseline. 
RESULTS 
Patient Characteristics 
Forty-two patients were evaluated, 21 receiving beef heparin 
and 21 pork heparin. The mean duration of therapy was 7.6 days with 
a standard deviation of 3.4 days. The age and sex characteristics of 
both groups did not differ. Heparin was administered for: Deep vein 
thrombosis, pulmonary embolism, peripheral arterial embolism or throm-
bosis and cerebral or myocardial infarction. 
Abnormal Serum Enzymes 
The following number of patients experienced serum enzyme values 
above the upper limits of normal of the clinical laboratories while on 
heparin: SGPT-33 percent (14 of 42 patients), SGOT-26 percent (11 of 
42 patients), LDH-33 percent (14 of 42 patients). Distribution of 
abnormal serum enzymes according to source were: SGOT-IO pork 
patients, 4 beef patients;' SGOT-6 pork patients, 5 beef patients; 
LDH-8 pork patients, 6 beef patients. The patients with the abnormal 
serum enzymes had a mean baseline and peak (± standard deviation) of: 
SGPT-baseline 38 ± 22 International Units (I.U.), peak 139 ± 98 I.U.; 
SGOT-baseline 22 ± 10 I.U., peak 106 ± 66 I.U.; LDH-baseline 280 ± 
116 I.U., peak 425 ± 233 I.U. (Tables 1, 2 and 3). Of the patients 
with abnormal levels, some had abnormal levels at baseline determina-
tion: SGPT-2 patients (both pork), LDH-5 patients (3 pork, 2 beef), 
SGOT-O patients. 
Rise in Serum Enzymes Above Baseline 
SGPT: Table 1 shows that 79 percent (31 of 39 patients) ex-
perienced a measurable rise above baseline of SGPT. Of these, 45 
percent were receiving pork heparin, 55 percent beef. The rise began 
by the second day of therapy and peaked between days 6 and 8. After 
day 8 the mean enzyme levels declined towards baseline through day 
10, but were still well above mean baseline levels (Illustration 1). 
There was a significant correlation (r = 0.881, P <0.001) between the 
day on which the peak value of SGPT was observed and the number of 
days the patient was treated with heparin (Illustration 3, Table 4). 
The mean peak ratio rise (± standard deviation) in SGPT was 2.94 
± 1.92 (Table 7). The mean peak ratio rise for all patients exhibit-
ing a rise while on heparin was significant when compared to baseline 
(P <0.05, t = 5.395, df = 30, paired samples). This significance also 
holds true if either product source is considered alone. There was 
no significant difference between the mean peak ratio of pork (2.68 ± 
10 
1.89) or beef (31.6 ± 1.92) heparin, but there was a tendency (only 
significant at a 0.10) for beef heparin treated patients to have peak 
ratio rises greater than the calculated mean (2.94 ± 1.92). (Table 
10A). 
SGOT: Table 2 shows that 76 percent (31 of 41 patients) ex-
perienced a measurable rise above baseline of SGOT. Of these, 52 
percent were receiving pork heparin, 48 percent beef. The rise began 
by the second day of therapy and peaked between days 4 and 6. After 
day 6 the mean enzyme levels declined towards baseline through day 
10, at which time they were essentially equal to the mean baseline 
levels (Illustration 1). There was a significant correlation (r = 
0.596, P <0.001) between the day on which the peak value of SGOT was 
observed and the number of days the patient was treated with heparin 
(Illustration 4, Table 5). 
The mean peak ratio rise (± standard deviation) in SGOT was 3.02 
± 1.95 (Table 8). The mean peak ratio rise for all patients exhibit-
ing a rise while on heparin was significant when compared to baseline 
(P <0.05, t = 5.997, df = 30, paired samples). This significance 
also holds true if either product source is considered alone. There 
was no significant difference between the mean peak ratio of pork 
(3.21 ± 2.20) or beef (2.83 ± 1.64) heparin (P >0.05, t = 0.799, df = 
29, independent samples), and neither had a greater tendency to cause 
peak ratio rises larger than the calculated mean ratio (3.02 ± 1.95). 
(Table 10B). 
Compared on the basis of mean peak ratios (Table 11), SGPT was 
no different that SGOT (P >0.05, t = 0.311, df = 26, paired samples). 
11 
However, if compared on the basis of mean peak units (Table 12), SGPT 
is significantly higher than SGOT (P <0.05, t = 2.528, df = 26, paired 
samples). 
LDH: Table 3 shows that 60 percent (23 of 38 patients) experi-
enced a measurable rise above baseline of LDH. Of these, 48 percent 
were receiving pork heparin, 52 percent beef. The rise began by the 
second day of therapy, and peaked by day 4. After day 4 the mean 
enzyme levels declined to baseline by day 8 and then leveled off 
through day 10 of therapy (Illustration 1). There was a significant 
correlation (r = 0.554, P <0.001) between the day on which the peak 
value of LDH was observed and the number of days the patient was 
treated with heparin (Illustration 5, Table 6). 
The mean peak ratio rise (± standard deviation) in LDH was 1.5 
±0.71 (Table 9). The mean peak ratio rise for all patients ex-
hibiting a rise while on heparin was significant when compared to 
baseline (P <0.05, t = 3.112, df = 22, paired samples). This sig-
nificance also holds true if either product source is considered 
alone. There was no significant difference between the mean peak 
ratio of pork (1.6 ± 0.89) or beef (1.4 ±0.48) heparin (P >0.05, 
t = 1.392, df = 21, independent samples), and neither had a greater 
tendency to cause peak ratio rises larger than the calculated mean 
ratio (1.5 ± 0.71). (Table 10C). 
Compared on the basis of mean peak ratios (Table 13), LDH is 
significantly less than SGPT (P <0.05, t = 3.232, df = 18, paired 
samples) and therefore SGOT. However, if compared on the basis of 
12 
mean peak units (Table 14), LDH is significantly greater than SGPT 
(P <0.05, t = 4.749, df = 18, paired samples) and therefore SGOT. 
Relationship of Peak to Baseline Values 
There was no relationship between the baseline values for the enzymes 
SGPT, SGOT or LDH and the peak enzyme ratios as evaluated by the 
Mantel-Haenszel test (P >0.05). (Tables 15A, 15B and 15C respective-
ly). Visual inspection of the raw data (Tables 1, 2 and 3) illus-
trates that lower baseline values before therapy do not, a priori, 
imply lower peak values and vice versa. 
Other Laboratory Parameters 
None of the other enzymes (e.g., alkaline phosphatase, GGTP) 
exhibited consistent variations during the course of heparin therapy. 
Other parameters measured with the serum chemistry profile demon-
strated no identifiable patterns of fluctuation while patients were 
receiving therapy. 
DISCUSSION 
In previous reports of heparin-induced increases in serum enzymes, 
investigators have limited observations to those patients developing 
abnormal levels. 1'^'^'By solely considering subjects demonstrat-
ing abnormal levels of serum enzymes in this study, an additional 48 
percent, who only showed a rise of enzymes above baseline, would have 
been ignored. Working with the premise of abnormal serum enzymes, a 
patient whose SGPT rose from 40 I.U. to 60 I.U., a 50 percent in-
crease, would be considered to have experienced a heparin-induced 
13 
side-effect. At the same time, a patient whose SGPT rose from 5 I.U. 
to 20 I.U., a 400 percent increase, would not be included in the 
analysis. To avoid this apparent ambiguity, all patients experienc-
ing serum enzyme rise were included in the evaluation. 
To more equitably compare patients according to their SGPT, 
SGOT and LDH rise, it was necessary to have equal and consistent 
baseline levels for these enzymes. International Units (I.U.) do 
not lend themselves to the concept of'a consistent baseline since 
each enzyme considered has a different range of normal in I.U., and 
one I.U. activity of SGPT does not equal one I.U. of SGOT or LDH, 
making comparison among the enzymes confusing. No relationship was 
found between subjects' baseline and peak enzyme values, so an ad-
justment factor could not be utilized. For these reasons the con-
cept of ratio increase over baseline was employed to achieve parity 
in the determination. Rises in enzymes could then be measured and 
evaluated as decimal increases over a baseline value of 1. 
The results of this study agree, in part, with previous reports. 
The percent of patients reported to experience rises in SGPT and SGOT 
1 9 11 
range from 62 percent to 89 percent ' ' which is consistent with 
the 76 percent to 79 percent reported here. The observation, in this 
study, that rises began by the second day of therapy is similar to 
1 9 11 
that seen in other determinations. ' ' The time required to reach 
the maximum level when considered in I.U. rise of enzymes, agrees 
9 
with Minar et al who saw SGPT peak at day 8 and SGOT at day 5, but 
is less than the results of Saffle et al 1 1 who reported peaks in 
14 
enzymes occurring around day 10. A decline in the enzyme levels after 
reaching their peak, as is depicted in the two graphs (Illustrations 1 
9 10 
and 2), has also been described in two previous studies. ' 
Though the data concerning the percent of patients, onset of rise 
and number of days to peak enzyme levels are in essential agreement 
with past investigations, other results of this study are divergent 
from the literature. Sonnenblick et al1 observed an increase in SGOT 
and SGPT in their study that averaged, respectively, 2 (range 1.5-2.5) 
and 3 (range 1.5-5) times the upper limits of normal. Saffle et al1 
noted peaks in LDH, SGOT and SGPT that averaged approximately 1.5, 3 
and 6 times baseline respectively. In the present study, enzyme 
peaks of 1.5 (for LDH) and 3. (for both SGPT and SGOT) times baseline 
are therefore lower than the results of Sonnenblick et al1 in 
general, and lower than the value of SGPT reported by Saffle et al.11 
The apparent discrepancy between this study and earlier work may, 
in part, be explained by the way in which the data were evaluated. 
Using 1 as the baseline for all three enzymes, and minimizing the con-
fusion of what an individual magnitude of I.U. rise means, could 
eliminate differences in the interpretation of these rises. There-
fore , 
as in the report by Saffle et al, SGPT could be two times 
greater than SGOT at their peaks if I.U. values for these two points 
are averaged, but not necessarily if ratio increases are considered. 
This is born out, in the current study, by the comparison, in I.U., 
of the mean peak rise of SGPT versus SGOT (Table 12) and LDH versus 
SGPT (Table 14). Compared on this basis SGPT can be shown to have a 
significantly greater mean peak than SGOT, and LDH a mean peak higher 
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than both SGPT and SGOT. Yet, when the same comparison is made on the 
basis of mean peak ratio of rise, SGPT equals SGOT (Table 11) and LDH 
is significantly less than either of these two (Table 13). Also, by 
including all patients exhibiting a rise over baseline, and not just 
those with abnormal values, the average peak levels in this study 
would be reduced. 
Different interpretations inherent in the evaluation by mean 
peak units rather than by mean peak ratios are well demonstrated by 
a comparison of the graphic representation of enzyme course with each 
method (Illustration 1 and 2). The graph utilizing I.U. (Illustration 
1) gives the enzyme course described previously. However, the graph 
of ratios (Illustration 2) depicts a different time course. There 
SGPT and SGOT both peak in 6 days,-while LDH still peaks at 4 days. 
Inspection of Illustration 2 reveals that the maximum peak ratio is 
2.5 for SGPT and 2.2 for SGOT, and that there is a significant dif-
ference between the two (P <0.05). These observations would appear 
to contradict statements made in the results section. However, in 
the determination of mean peak ratio of rise, each patient's ratio, 
regardless of the day of therapy it occurred, was utilized. The 
graph of ratio increase (Illustration 2) considers the mean ratio for 
all patients on the same day. Therefore day 6, though on the average 
representing the day of peak SGPT and SGOT, does not necessarily in-
clude all the maximal rises. 
Caution is advised in interpreting the course of heparin-induced 
effects on serum enzymes. Illustrations 1 and 2 show enzyme levels 
declining after attaining their peak levels, even though heparin was 
still being administered. It should be noted that these plots are 
based on the mean values of all patients experiencing an enzyme rise 
while on heparin. Many patients received only 4 or 6 days of therapy, 
therefore during the later time periods represented on the graphs 
fewer patients were still receiving heparin (see Tables 16A and B for 
n at each data point). It is possible that the mean value of this 
small sample is not representative of the true population mean. If 
there had been more patients who received heparin for 8 and 10 days, 
instead of the 5 or fewer that could be evaluated in this study, 
their peak enzymes might all be higher and therefore raise the pre-
sent mean enzyme values. The addition of the patients remaining to 
be studied, if they are treated for 8 to 10 days, may subsequently 
modify or cancel this apparent decline in peak serum enzymes. 
The study by Saffle et al 1 1 refers to a difference between the 
pork and beef heparin in the incidence of effect on serum enzymes. 
Pork heparin induced a rise in serum enzymes for 93 percent of 
patients receiving that source, while only 37 percent of beef heparin 
treated patients experienced this effect. The difference between the 
two groups was significant at a 0.05. This study did not identify 
this same trend, the maximum difference between products being a 10 
percent greater number of patients with increased SGPT who received 
beef heparin. The only difference attributable to heparin source in 
this study was a tendency for beef heparin to cause peak ratio in-
creases that were beyond the calculated mean. This difference was 
not significant at the a 0.05 level. 
In a discussion of a possible drug-induced side-effect, it is 
important to establish cause. More than 60 percent of the treated 
patients in this study had an increase in at least one serum enzyme 
during heparin therapy. Implicating heparin as the cause can best be 
done by a review of the subjective and objective data. 
Measures of correlation were performed to determine if there was 
a relationship between the number of days the patients were treated 
and the peak values of their enzymes (Illustrations 3, 4, 5 - Tables 
4, 5 and 6). For each patient the day of peak enzyme value was re-
lated to the number of days on heparin. Implications of this re-
lationship are that if heparin is causing the rise, the peak values 
should come near the last day of therapy since enzymes should begin 
to decline once heparin is discontinued. This is supported by Saffle 
et al 1 1 who saw serum enzymes rise during the 10 days their patients 
were treated, and decline when heparin was stopped, and Sonnenblick 
et al1 who saw the same pattern. For each enzyme examined in the cur-
rent study, the correlation coefficient (r) was significant at P < 
0.001. If the rationale above is appropriate, then this high cor-
relation supports a relationship between heparin administration and 
ris.e in serum enzymes. Although this hypothesis speaks against the 
observed decline in serum enzymes, even when therapy is continued, 
the caution about an artifactual decline is re-emphasized. 
The correlation coefficient for SGPT was higher than for SGOT, 
and SGOT about equal to LDH (r = 0.881, 0.586, and 0.554, respective-
ly). SGPT is an enzyme contained almost entirely in hepatocytes, 
while SGOT and LDH are found in cells of many more muscle and organ 
18 19 20 
systems. ' ' The better correlation for SGPT may therefore show 
not only a relation to heparin, but also imply that the side-effect is 
mediated upon the liver. Further subjective evidence is gained from 
the enzyme profile exhibited by the patients in this study. The 
18 
overall pattern (Illustration 2) of increased SGPT and SGOT (with SGPT 
higher than SGOT) coupled'with a smaller increase in LDH is felt to be 
4 8 
characteristic of hepatocellular damage. ' 
The possibility exists that the rise in serum enzymes observed in 
this study were induced by drugs other than heparin that the patients 
were receiving. Many of the medications used by some of the patients 
in this study have been reported to be hepatotoxic. Examples of the 
21 22 
more commonly implicated of these medications are: anesthetics, ' 23 23 24 aspirin, acetaminophen, methylctopa, nonsteroidal anti-inflam-
21,25 . „ . 21,26 . 27 . , .. 28 matory agents, phenytom, sulfa drugs and furosemide. 
In evaluating all the patients, it would not appear that these other 
drugs were the cause of the .observed results. In the majority of 
patients these drugs were started long before heparin therapy so that 
they would be expected to raise baseline enzyme values and not study 
period values. Even though many of these agents are known to have a 
29 
latent period before exhibiting hepatotoxicity, the chance that 
they coincidently manifested this side-effect, during a 4 to 10 day 
period, and in all patients exhibiting a rise in serum enzymes, is 
unlikely. Also, many of these hepatotoxic agents are known to cause 
22 29 
a cholestatic type injury ' while the enzyme pattern in this in-
vestigation was consistent with hepatocellular damage. There were 
not enough of the subjects consistently receiving these hepatotoxic 
agents to explain the rise in greater than 60 percent of the popula-
tion. Finally, many of the patients who did not experience a rise 
in serum enzymes were also taking some of the medications. 
19 
An essential consideration in attempting to delegate a side-
effect to a drug is the question of whether it is a drug effect or a 
drug interference with a laboratory test. All patients in this study 
received heparin, but only a portion had a rise in serum enzymes. 
This observation is further supported by the study of Sonnenblick et 
al1 who in their investigation tested the possibility of interference 
with liver function tests. They performed these tests on paired blood 
samples from normal controls, to one of which was added heparin. The 
determination showed no difference -between samples. Saffle et al 1 1 
went one step further by testing possible differences for beef or pork 
heparin. No difference was apparent between any of the samples. 
Although it appears from this and previous studies that heparin 
administration predictably causes a rise in serum enzymes, the clini-
cal significance of this side-effect is unproven. Unlike other heparin-
induced adverse effects, which have proven morbidity and mortali-
30 31 32 
ty ' ' no clinical illness has been reported to occur from a 
heparin-induced rise in serum enzymes. No patient in this study de-
veloped a hepatitis-like syndrome while receiving heparin. Perhaps 
the biggest clinical concern is the possible interference in the 
diagnosis of pulmonary embolism, dermatomyositis, polymyositis, 
hepatic damage and myocardial infarction. Since the diagnosis or 
monitoring of these disease states is often aided by obtaining serum 
enzymes'^'^'^' ^  heparin administration may obviate the use of a 
valuable clinical tool. 
CONCLUSION 
Heparin administration has a high probability of inducing a rise 
in serum enzymes. This effect is believed to be mediated on the liver 
20 
by an unknown mechanism, and is not an interference with a laboratory 
determination. SGPT, SGOT and LDH begin to rise within 2 days of be-
ginning therapy, and reach a peak in 4 days (for LDH) to between 6 and 
8 days (for both SGPT and SGOT). The enzymes do not tend to increase 
more than 1.5 (for LDH) or 3 (for both SGPT and SGOT) times baseline. 
Neither pork nor beef heparin causes this effect more commonly than 
the other. Current observations appear to indicate that enzymes de-
cline toward baseline after reaching peak values, even if heparin ad-




RAW DATA TABLES 
Range of Normals 
Table 1. Serum Glutamic Pyruvic Transaminase (SGPT) 
4-46 ± 20% International Units 
Table 2. Serum Glutamic Oxaloacetic'Transaminase (SGOT) 
1-51 ± 20% International Units 
Table 3. Lactic Dehydrogenase (LDH) 
112-247 ± 10% International Units 
Legend 
* 







^ pork heparin 
^ ^ receiving heparin 
^ ^ no values obtained 
NOTE: Patient numbers 13 and 37 not included - these numbers assigned 
to blanks in data set 
Table 1 
Patient Number and Heparin Source 
<» II >• 












B P P B P P B B P P B P B B P B P P B P B 
1 2 3 4 5 6 7 8 9 10 11 12 14 15 16 17 18 19 20 21 22 
Base 
t i n e 40 35 106 7 25 40 13 16 5 25 43 37 19 47 33 23 46 31 21 45 20 
1 ( 3 4 ) 
2 ( 2 5 ) ( 3 1 ) ( 8 1 ) ( 9 ) (32) ( 1 8 ) ( 1 0 ) ( 2 9 ) (339 ) ( 3 9 ) ( 1 6 ) ( 3 4 ) ( 2 6 ) ( 2 0 ) ( 6 0 ) ( 4 3 ) ( 2 4 ) ( 4 4 ) ( 2 3 ) 
3 ( 3 2 ) ( 1 0 ) (107 ) ( 2 9 0 ) ( 1 5 ) 
31 ( 3 3 ) ( 2 7 7 ) ( 2 1 ) ( 3 4 ) ( 1 7 ) ( 1 2 ) ( 3 8 ) ( 2 5 ) 35 ( 4 5 ) (29) ( 9 3 ) (-) (21) 
5 - ( 6 5 ) ( 2 1 ) 187 ( 3 3 8 ) ( 6 5 ) ( 2 4 ) 
6 ( 2 9 ) ( 3 5 ) 170 48 ( 6 3 ) ( 2 5 ) ( 1 9 ) ( 6 1 ) 39 (114 ) ( 4 3 ) 35 
7 ( 7 5 ) 68 25 207 45 ( 2 4 ) 
S ( 3 2 ) ( 4 1 ) 73 47 27 ( 7 3 ) 208 ( 3 5 ) - -
9 108 (-) 36 
10 ( 2 1 ) ( 6 0 ) 55 ( 6 2 ) 180 (-) 
( 2 5 ) 86 
( 1 7 ) 
( 9 ) 
(20) 
( - ) 
( 1 5 ) 
53 
1 1 2 \ 32 
71 
N> 
* 0 0 « ? 0 • 
Table 1 (continued) 












































L i n e 13 23 21 24 8 41 11 20 21 52 13 73 15 23 24 0 31 30 31 10 21 
1 ( 3 9 ) ( 1 8 ) ( 4 7 ) 
2 ( 3 3 ) ( 6 4 ) ( 1 8 ) <-> ( 1 6 ) ( 1 2 ) ( 1 7 ) ( 1 2 ) ( 1 7 ) (-) ( 2 8 0 ) ( 2 6 ) ( 3 2 ) ( 2 7 ) ( 1 6 ) 
3 ( 3 3 ) ( 3 8 ) ( 1 4 ) ( 2 3 ) ( 4 7 ) 
4 ( 4 9 ) ( 2 9 ) ( 8 7 ) ( 1 6 ) (-) ( 1 6 ) ( 1 2 1 ) ( 3 5 ) (-) ( 3 0 ) ( 3 4 ) ( 3 7 ) ( 1 4 ) ( 4 5 ) ( 4 0 ) ( 3 0 ) ( 1 6 ) ( 1 7 ) 
5 ( 2 9 ) ( 1 2 0 ) 34 9 ( 2 4 ) (-) ( 1 7 ) 
6 123 ( 6 0 ) 158 21 15 ( 1 6 7 ) ( 4 1 ) ( 4 0 ) ( 1 0 2 ) ( 9 5 ) ( 4 0 ) 77 40 ( 4 3 ) ( 2 8 ) 
7 ( 4 9 ) 85 ( 3 2 ) 
8 107 40 (106 ) 36 30 ( 8 2 ) - ( 4 5 ) 
9 94 ( 6 4 ) ( 4 5 ) ( 1 9 ) 48 
10 25 121 36 ( 4 8 ) ( 4 6 ) 























Patient Number and Heparin Source 
B P P B P P B B P P P B B B P B P P B P B 














1 1 2 
13 
14 
35 45 52 7 8 53 1 7 9 10 19 33 22 25 22 20 19 24 1? 23 31 21 
( 3 5 ) ( 3 0 ) 
(16) ( 2 2 ) ( 4 3 ) ( 1 0 ) ( 2 4 ) ( 2 2 ) ( 1 0 ) ( 2 0 ) ( 3 9 ) ( 3 3 ) ( 1 8 ) ( 1 9 ) ( 1 7 ) (11) ( 1 2 7 ) ( - ) ( 2 6 ) ( 2 9 ) ( 1 9 ) 
( 2 9 ) ( 2 2 ) ( 2 6 1 ) ( 2 3 ) 
CO) (17) 46 
( 1 7 ) ( 3 2 ) 15 
( 1 0 ) ( 4 8 ) 
( 1 3 ) 73 
(18) 
( 3 7 ) 
( 3 9 ) 
59 
(112) ( 9 4 ) 
(18) 
( 1 4 ) 
(17) ( 3 4 ) <18) ( 2 2 ) ( 2 2 ) 32 ( 3 1 ) ( 1 8 ) ( 6 1 ) 
( 1 5 ) 38 ( 2 1 2 ) 
24 ( 5 8 ) (16) ( 2 5 ) ( 4 4 ) 23 ( 5 9 ) ( 3 0 ) 16 
52 21 64 
22 22 ( 3 7 ) 
39 ( 2 5 ) 
22 
95 ( 1 7 ) 
( - ) 
55 ( - ) 
,2*4 20 
( 1 5 ) 
( 3 6 ) ( 2 4 ) 












( 1 4 ) 
( 1 7 ) 
( - ) 




0 * * 0 0 * * 0 
Table (continued) 

























































L i n e 13 17 20 11 18 20 11 17 20 25 22 54 12 14 20 0 20 18 19 22 17 
1 ( 7 3 ) ( 1 8 ) ( 2 2 ) 
2 ( 1 5 ) ( 5 6 ) ( 2 0 ) (-) ( 4 2 ) ( 1 1 ) (29) ( 1 2 ) ( 1 9 ) (-) ( 1 8 ) ( 2 1 ) ( 1 9 ) ( 7 4 ) ( 2 0 ) 
3 ( 2 0 ) (57) ( 3 ) ( 2 2 ) ( 3 9 ) 
u ( 2 9 ) ( 4 0 ) ( 5 0 ) ( 2 6 ) (-) ( 1 4 ) (61) (28) (-) ( 1 9 ) ( 2 5 ) ( 2 4 ) (9 ) ( 3 1 ) ( 2 2 ) ( 1 9 ) ( 2 2 ) ( 2 1 ) 
5 ( 1 8 ) ( 8 2 ) 56 13 ( 2 7 ) (-) ( 1 6 ) 
6 70 ( 3 6 ) 99 19 13 ( 6 2 ) ( 2 7 ) ( 2 1 ) ( 6 2 ) ( 4 0 ) ( 2 7 ) 51 21 ( 2 5 ) ( 3 1 ) 
7 ( 2 7 ) 31 ( 1 4 ) 
8 61 17 ( 2 9 ) 17 14 ( 2 1 ) - ( 3 4 ) 
9 29 ( 1 4 ) ( 1 9 ) ( 5 ) 22 
10 48 17 ( 1 2 ) ( 2 9 ) 






















































B i s e 
l . ine 256 207 201 186 120 592 213 150 193 312 470 232 227 132 180 158 198 341 179 206 235 
1 (242 ) ( 3 6 6 ) 
2 ( 1 8 5 ) ( 2 1 9 ) ( 1 8 1 ) ( 1 8 3 ) (482 ) ( 2 2 1 ) ( 1 9 8 ) (384 ) (360 ) (197 ) ( 2 0 8 ) ( 1 4 9 ) (136 ) ( 1 5 9 ) (858 ) (222 ) ( 1 5 9 ) ( 3 0 1 ) ( 1 7 1 ) 
3 ( 1 5 4 ) (219 ) (259 ) (-) ( 1 5 6 ) 
4 ( 2 0 8 ) ( 2 1 3 ) ( 4 0 8 ) (210 ) (294 ) ( 2 8 7 ) ( 2 7 6 ) ( 3 7 2 ) (214 ) 181 ( 1 6 4 ) (-) (545 ) (-) ( 1 7 6 ) 
5 ( 1 9 5 ) ( 2 1 6 ) 360 (291 ) ( 3 1 5 ) (18C) 
6 (-) ( 1 7 5 ) 166 312 ( 2 6 7 ) ( 3 7 4 ) ( 2 0 0 ) ( 1 3 5 ) 151 ( 4 6 8 ) (295 ) 177 
7 (-) 249 233 247 300 ( 1 7 1 ) 
8 ( 1 9 4 ) ( 2 2 6 ) 130 - 333 ( 1 6 7 ) 382 (-) 
9 227 291 
10 ( 1 6 0 ) (200 ) 373 ( 1 2 8 ) 312 
11 











18 ( 2 2 9 ) 
19 




0 * * * 0 * * 0 0 0 * ? 0 * 0 fo 
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Table 4. Serum Glutamic Pyruvic Transaminase 
Values for Correlation Coefficient Calculation 
(X-X) (Y-Y) (X-X) (Y-Y) 
-3.97 -3.52 13.97 
-1.97 -3.52 6.93 
-1.97 -1.52 2.99 
-1.97 -1.52 2.99 
-1.97 -1.52 2.99 
-1.97 -1.52 2.99 
-1.97 -1.52 ' 2.99 
-1.97 -1.52 2.99 
-1.97 -1.52 2.99 
0.03 -1.52 -0.04 
0.03 -1.52 -0.04 
-0.97 -0.52 0.50 
-0.97 -0.52 0.50 
-0.97 -0.52 0.50 
-0.97 -0.52 0.50 
-0.97 -0.52 0.50 
0.03 0.48 0.01 
0.03 0.48 0.01 
0.03 0.48 0.01 
0.03 0.48 0.01 
0.03 0.48 0.01 
0.03 0.48 0.01 
2.03 0.48 0.97 
4.03 0.48 1.93 
1.03 1.48 1.52 
1.03 1.48 1.52 
1.03 1.48 1.52 
4.03 2.48 9.99 
3.03 3.48 10.54 
30 
Table 4. (continued) 
(X-X) (Y-Y) (X-X) (Y-Y) 
4.03 4.48 18.05 
4.03 4.48 18.05 
Ex 108.40 
Ex* 132.97 113.74 
Legend 
(X-X) = days on heparin - mean days on heparin 
(Y-Y) = day to peak - mean day to peak 
Ex = sum of entries in a column 
Ex = sum of the squares of entries in a column 
Table 5. Serum Glutamic Oxaloacetic Transaminase 
Values for Correlation Coefficient Calculation 
(X-X) (Y-Y) (X-X) (Y-Y) 
-1.81 -3.42 6.19 
-3.81 -2.42 9.22 
-1.81 -2.42 4.38 
-1.81 -2.42 4.38 
-1.81 -2.42 4.38 
0.19 -2.42 -0.46 
0.19 -2.42 -0.46 
4.19 -1.42 -5.95 
-1.81 -0.42 0.76 
-1.81 -0.42 0.76 
-1.81 -0.42 0.76 
-1.81 -0.42 , 0.76 
-1.81 -0.42 0.76 
-1.81 -0.42 0.76 
0.19 -0.42 -0.08 
0.19 -0.42 -0.08 
-0.81 0.58 -0.47 
-0.81 0.58 -0.47 
-0.81 0.58 -0.47 
-0.81 0.58 -0.47 
-0.81 0.58 -0.47 
0.19 1.58 0.30 
0.19 1.58 0.30 
0.19 1.58 0.30 
2.19 1.58 3.46 
3.19 1.58 5.04 
4.19 1.58 6.62 
4.19 1.58 6.62 
32 
Table 5. (continued) 
(X-X) (Y-Y) (X-X) (Y-Y) 
1.19 2.58 3.07 
1.19 2.58 3.07 
4.19 3.58 15.00 
* 
Ex 67.51 
Ex2 138.84 95.55 
Legend 
(X-X) = days on heparin - mean days on heparin 
(Y-Y) = day to peak - mean days to peak 
Ex = sum of entries in a column • 
2 
Ex = sum of the squares of entries in a column 
33 
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Table 6. Lactic Dehydrogenase 
Values for Correlation Coefficient Calculation 
(X-X) (Y-Y) (X-X) (Y-Y) 
-2.5 -3.1 7.75 
4.5 -3.1 -13.95 
-3.5 -2.1 7.35 
-1.5 -2.1 3.15 
-1.5 -2.1 3.15 
-1.5 -2.1 3.15 
0.5 -2.1 -1.05 
0.5 -2.1 -1.05 
-0.5 -1.1 0.55 
-0.5 -1.1 0.55 
-1.5 -0.1 0.15 
-1.5 -0.1 • 0.15 
-1.5 -0.1 0.15 
0.5 -0.1 -0.05 
-0.5 0.9 -0.45 
-0.5 0.9 -0.45 
-0.5 0.9 -0.45 
0.5 1.9 0.95 
0.5 1.9 0.95 
0.5 1.9 0.95 
1.5 2.9 4.35 
4.5 3.9 17.55 
4.5 5.9 26.55 
Ex 59.95 
Ex2 97.75 119.82 
Legend 
(X-X) = days on heparin - mean days on heparin 
(Y-Y) = day to peak - mean days to peak 
£x2 = sum of entries in a column 
Ex = sum of squares of entries in a column 
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Table 7. Serum Glutamic Pyruvic Transaminase 
Ratio of Peak Enzyme Increase to Baseline 
Type // Ratio Type # Ratio 
1 NR B 23 3.8 
p 2 1.7 P 24 2.8 
p 3 2.6 P 25 2.9 
B 4 3.0 B 26 5.0 
P 5 3.0 ' ^ B 27 2.0 
6 NR 28 NR 
B 7 4.8 ' P 29 1.4 
B 8 1.6 30 NR 
P 9 2.4 31 NR 
P 10 1.5 P 32 3.2 
B 11 7.9 B 33 2.3 
P 12 9.1 34 NR 
13 NR B 35 6.8 
B 14 1.3 B 36 4.1 
15 NR 37 NR 
P 16 2.2 B 38 1.9 
B 17 1.7 39 UE 
P 18 2.0 40 UE 
19 UE P 41 1. 3 
20 NR B 42 1.4 
P 21 1.4 B 43 2.7 
B 22 1.2 B 44 2.2 
All heparin patients with rise - X_= 2.94 SD = 1.92 n = 31 
Pork heparin patients with rise - X = 2.68 SD = 1.89 n = 14 
Beef heparin patients with rise - X = 3.16 SD = l."92 n = 17 
Legend 
# = patient number 
P = pork B = beef 
NR = no rise (i.e., patient's enzyme did not increase above baseline) 
UE = unevaluable (i.e., results of laboratory tests suspect or missing) 
* each patient's maximum enzyme value, regardless of day occurring, 
compared to entry enzyme value 
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Table 8. Serum Glutamic Oxaloacetic Transaminase 
Ratio of Peak Enzyme Increase to Baseline 
Type II Ratio Type # Ratio 
1 NR B 23 2.1 
2 NR P 24 3.3 
p 3 5.0 P 25 2.0 
B 4 3.3 B 26 7.4 
P 5 4.9 B 27 2.3 
6 NR B 28 3.6 
B 7 3.4 P 29 1.2 
B 8 1.7 30 NR 
P 9 1.8 P 31 1.4 
P 10 1.2 P 32 2.5 
B 11 1.2 B 33 1.3 
P 12 9.6 • 34 NR 
13 NR B 35 5.2 
14 NR B 36 2.8 
15 NR 37 NR 
P 16 2.2 B 38 1.4 
17 NR 39 UE 
P 18 5.3 P 40 1.6 
P 19 4.9 P 41 1.2 
20 NR B 42 1.3 
P 21 3.3 B 43 3.4 
22 NR B 44 2.0 
All heparin patients with rise - X_= 3.02 SD - 1.95 n = 31 
Pork heparin patients with rise - X = 3.21 SD = 2.20 n = 16 
Beef heparin patients with rise - X = 2.83 SD = 1.64 n = 15 
Legend 
// = patient number 
P = pork B = beef 
NR = no rise (i.e., patient's enzyme did not increase above baseline) 
UE = unevaluable (i.e., results of laboratory tests suspect or missing) 
*each patient's maximum enzyme value, regardless of day occurring, 
compared to entry enzyme value 
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Table 9. Lactic Dehydrogenase 
Ratio of Peak Enzyme Increase to Baseline 
Type # Ratio Type # Ratio 
1 NR B 23 1.2 
p 2 1.1 P 24 1.1 
p 3 2.0 25 NR 
B 4 1.1 B 26 1.2 
5 UE B 27 1.4 
6 NR 28 UE 
B 7 1.3 29 NR 
B 8 1.5 P 30 1.2 
P 9 1.4 P 31 1.2 
P 10 1.2 32 NR 
11 NR B 33 1.5 
P 12 1.2 * P 34 1.2 
13 NR B 35 1.1 
14 NR B 36 1.1 
B 15 1.1 37 NR 
16 NR 38 NR 
17 NR 39 UE 
P 18 4.3 40 NR 
19 UE 41 NR 
20 NR 42 NR 
P 21 1.5 B 43 2.8 
22 NR B 44 1.1 
All heparin patients with rise - X_= 1.5 SD = 0.71 n = 23 
Pork heparin patients with rise - X = 1.6 SD = 0.89 n = 11 
Beef heparin patients with rise - X = 1.4 SD = 0.48 n = 12 
Legend 
# = patient number 
P = pork B = beef 
NR = no rise (i.e., patient's enzyme did not increase above baseline) 
UE = unevaluable (i.e., results of laboratory test suspect or missing) 
* each patient's maximum enzyme value, regardless of day occurring 
compared to entry enzyme value 
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Table 10. Relation of Heparin Source to Peak/Baseline Ratios Greater 
Than the Mean Peak/Baseline Ratio for Serum Glutamic Pyru-
vic Transaminase (SGPT), Serum Glutamic Oxaloacetic Trans-
aminase (SGOT) and Lactic Dehydrogenase (LDH) 
Heparin Source 
Beef Pork 





(A)* »• P = 0.095 Fisher's Exact Test 
Heparin Source 
Beef • Pork 
Ratio of peak 1-3 
SGOT to 
Baseline 3.1->5 
(B) P > 0.10 Fisher's Exact Test 
Heparin Source 
Beef Pork 
Ratio of peak 1-1.4 9 8 
LDH to 
Baseline 1.5->2 3 3 
(C) P > 0.10 Fisher's Exact Test 
Legend 
Numbers in boxes represent the numbers of patients receiving the 
indicated heparin source who had peak enzyme ratios in the indicated 
range. For example, 10 patients receiving beef heparin had peak 
SGPT ratios between 1-3. 
Table 11. Peak/Baseline Ratio Serum Glutamic Pyruvic Transaminase 
(SGPT) Versus Peak/Baseline Ratio Serum Glutamic Oxalo-
acetic Transaminase (SGOT) 
type # SGPT SGOT d 
1 NA NA NA 
2 NA NA NA 
P 3 2.6 5.0 -2.4 
B 4 3.0 
** 
3.3 -0.3 
P 5 3.0 4.9 -1.9 
6 NA NA NA 
B 7 4.8 3.4 1.4 
B 8 1.6 1.7 -0.1 
P 9 2.4 1.8 0.6 
P 10 1.5 1.2 0.3 
B 11 7.9 1.2 6.7 
P 12 9.1 9.6 -0.5 
13 NA NA NA 
14 NA NA NA 
15 NA • NA NA 
P 16 2.2 2.2 0 
17 NA NA NA 
P 18 2.0 5.3 -3.3 
19 NA NA NA 
20 NA NA NA 
P 21 1.4 3.3 -1.9 
22 NA NA NA 
B 23 ' 3.8 2.1 1.7 
P 24 2.8 3.3 -0.5 
P 25 2.9 2.0 0.9 
B 26 5.0 7.4 -2.4 
B 27 2.0 2.3 -0.3 
28 NA NA NA 





# SGPT SGOT d 
30 NA NA NA 
31 NA NA NA 
P 32 3.2 2.5 0.7 
B 33 2.3 1.3 1.0 
34 NA NA NA 
B 35 6.8 5.2 1.6 
B 36 4.1 2.8 1.3 
37 NA NA NA 
B 38 1.9 1.4 0.5 
39 NA NA NA 
40 NA NA NA 
P 41 1.3 1.2 0.1 
B 42 1.4 1.3 0.1 
B 43 2.7 3.4 -0.7 
B 44 2.2 2.0 0.2 
n = 27 
(1) Sum of differences = 3 
(2) Mean difference (d) = 0.11 (l)/ 'n 
(3) Sum of squares of differences = 87.90 
(4) 2 (Sum of differences) /n = 0.33 
Cl)2/ 
'n 
(5) Sum of squares about mean = 87.57 [ (3)—(4) 
(6) s 2 d 3.36 (5), ' n-1 
Legend 
# = patient number 
P = pork heparin B = beef heparin d = SGPT-SGOT 
S2(j= standard deviation squared 
NA = not applicable (i.e., data unevaluable, neither enzyme rose, or 
one of the pair did not rise) 
n = number of pairs evaluated 
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Table 12. Peak Unit Value Serum Glutamic Pyruvic Transaminase (SGPT) 
Versus Peak Unit Value Serum Glutamic Oxaloacetic 
Transaminase (SGOT) 
type # SGPT SGOT d 
1 NA NA NA 
2 NA NA NA 
P 3 277 261 16 
B 4 21 23 -2 
P 5 75 39 36 
6 NA NA NA 
B 7 63 58 5 
B 8 21 15 6 
P 9 12 18 -6 
P 10 38 22 16 
B 11 339 39 300 
P 12 338 <• 212 126 
13 NA NA NA 
14 NA NA NA 
15 NA NA NA 
P 16 73 44 29 
17 NA NA NA 
P 18 114 127 -13 
19 NA NA NA 
20 NA NA NA 
P 21 65 36 29 
22 NA NA NA 
B 23 49 27 22 
P 24 64 56 8 
P 25 60 40 20 
B 26 120 82 38 
B 27 16 42 -26 
28 NA NA NA 
P 29 16 13 3 
30 NA NA NA 
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Table 12. (continued) 
Type # SGPT SGOT d 
31 NA NA NA 
P 32 167 62 105 
B 33 41 29 12 
34 NA NA NA 
B 35 102 62 40 
B 36 95 40 55 
37 NA NA NA 
B 38 45 27 18 
39 NA NA NA 
40 NA NA NA 
P 41 40 22 18 
B 42 43 25 18 
B 43 27 74 -47 
B 44 46 34 12 
n = 27 
(1) Sum of differences = 838 
(2) Mean difference (d) = 31.04 ( 1 >'n 
(3) Sum of squares of differences = 131832 
(4) 2 (Sum of differences) /n = 26009 <»
2/n 
(5) Sum of squares about mean = 105823 [ (3)-(4) 
(6) s2a 4070 (5)/n-! 
Legend 
# = patient number 
P = pork heparin B = beef heparin d = SGPT-SGOT 
S^^ standard deviation squared 
NA = not applicable (i.e., data unevaluable, neither enzyme rose, or 
one of the pair did not rise) 
n = number of pairs evaluated 
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Table 13. Peak/Baseline Ratio Serum Glutamic Pyruvic Transaminase 
(SGPT) Versus Peak/Baseline Ratio Lactic Dehydrogenase 
(LDH) 
rYPE # SGPT LDH d 
1 NA NA NA 
p 2 1.7 1.1 0.6 
p 3 2.6 2.0 0.6 
B 4 3.0 1.1 1.9 
5 NA NA NA 
6 NA NA NA 
B 7 4.8 1.3 3.5 
B 8 1.6 1.5 0.1 
P 9 2.4 1.4 1.0 
P 10 1.5 1.2 0.3 
11 NA NA NA 
P 12 9.1 1.2 7.9 
13 NA NA NA 
14 NA NA NA 
15 NA NA NA 
16 NA NA NA 
17 NA NA NA 
P 18 2.0 4.3 -2.3 
19 NA NA NA 
20 NA NA NA 
P 21 1.4 1.5 -0.1 
22 NA NA NA 
B 23 3.8 1.2 2.6 
P 24 2.8 1.1 1.7 
25 NA NA NA 
B 26 5.0 1.2 3.8 
B 27 2.0 1.4 0.6 
28 NA NA NA 
29 NA NA NA 
30 NA NA NA 
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Table 13. (continued) 
Type # SGPT LDH d 
31 NA NA NA 
32 NA NA NA 
B 33 2.3 1.5 0.8 
34 NA NA NA 
B 35 6.8 1.1 5.7 
B 36 4.1 1.1 3.0 
37 NA NA NA 
38 NA NA NA 
39 NA NA NA 
• 40 NA NA NA 
41 NA NA NA 
42 NA NA NA 
B 43 2.7 2.8 -0.1 
B .44 2.2 1.1 1.1 
n = 19 
(1) Sum of differences = 32.7 
(2) Mean difference (d) = 1.72 ( 1 ) / „ 
(3) Sum of squares of differences = 153.19 
(4) 2 (Sum of differences) /n = 56.28 
<«2/ ' n 
(5) Sum of squares about mean = 96.91 [(3)-(4)] 
(6) s2d 5.38 (5)/ n-1 
Legend 
# = patient number 
?2 = pork heparin B = beef heparin d = SGPT-LDH 
S standard deviation squares 
NA = not applicable (i.e., data unevaluable, neither enzyme rose, or 
one of the pair did not rise) 
n = number of pairs evaluated 
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Table 14. Peak Unit Value Serum Glutamic Pyruvic Transaminase (SGPT) 
Peak Unit Value Lactic Dehydrogenase (LDH) 
Type # LDH SGPT d 
1 NA NA NA 
p 2 226 60 166 
p 3 408 277 131 
B 4 210 21 189 
5 NA NA NA 
6 NA NA NA 
B 7 287 63 224 
B 8 219 21 198 
P 9 276 12 264 
P 10 384 38 346 
11 NA NA NA 
P 12 291 338 -47 
13 NA NA NA 
14 NA NA NA 
15 NA NA NA 
16 NA NA NA 
17 NA NA NA 
P 18 858 114 744 
19 NA NA NA 
20 NA NA NA 
P 21 315 65 250 
22 NA NA NA 
B 23 229 49 180 
P 24 332 64 258 
25 NA NA NA 
B 26 277 120 157 
B 27 352 16 336 
28 NA NA NA 
29 NA NA NA 
30 NA NA NA 
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Table 14. (continued) 
Type // LDH SGPT d 
31 NA NA NA 
32 NA NA NA 
B 33 291 41 250 
34 NA NA NA 
B 35 167 102 65 
B 36 256 95 161 
37 NA NA NA 
38 NA NA NA 
39 NA NA NA 
40 NA NA NA 
41 NA NA NA 
42 NA NA NA 
B 43 1083 27 1056 
B . 44 202 46 156 
n = 19 
(1) Sum of the differences = 5084 
(2) Mean difference (d) = 267.58 
(3) Sum of squares of differences = 2446102 
(4) 2 (Sum of differences) /n = 1360371 
(5) Sum of squares about mean = 1085731 
(6) s 2 d 60318 
Legend 
# = patient number 
P = pork heparin B = beef heparin d = LDH-SGPT 
standard deviation squared 
NA = not applicable (i.e., data not evaluable, neither enzyme rose, 
or one of the pair did not rise) 
n = number of pairs evaluated 
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Table 15. Baseline Enzyme Values' Relation to Observed Peak Ratios 
Baseline Serum Glutamic 
Pyruvic Transaminase Units 
0 - 2 0 21-30 31->50 
1-2 4 4 3 
2.1-3 5 4 4 
3.1-4 1 0 0 
4.l->5 2 2 1 -
(A) P >0.05 - Mante1-Haensze1 
Baseline Serum Glutamic 
Oxaloacetic Transaminase Units 
0 - 2 0 21-30 31->50 
1-2 12 1 1 
2.1-3 4 1 0 
3.1-4 4 1 0 
4.l->5 4 2 1 
(B) P >0.05 - Mante1-Haenszel 
Baseline Lactic 
Dehydrogenase Units 
0-200 201-300 301->500 
1.0-1.2 6 7 1 
1.3-1.4 1 2 0 
1.5-1.6 2 1 0 
1.6->2 1 1 1 
(C) P >0.05 - Mante1-Haenszel 
Legend 
Numbers in boxes represent the number of patients in the indicated 
baseline range who had peak ratios of rise of the indicated magni-
tude. For example, 4 patients with baseline SGPT between 0.20 had 
peak ratios of rise between 1-2. 
Table 16A. Unit Values for Individual Enzymes of All Patients Exhibiting Rises While on 
Heparin Therapy 




Therapy X SD n X SD n X SD n 
Baseline 26 19 31 18 9 31 
\ 
216 57 23 
2 40 62 26 31 26 23 314 244 18 
4 48 54 24 40 50 22 336 197 15 
6 64 40 14 40 15 13 266 94 9 
8 69 24 5 28 8 5 204 27 3 
10 54 7 4 22 7 3 204 4 3 






deviation n = 
beginning heparin 
number of patients evaluated 
Table 16B. Peak/Baseline Ratio Values for Individual Enzymes of All Patients Exhibiting Rises 










Baseline 1 0 31 1 0 
s 
31 \ 1 0 23 
2 1.52 1.41 26 1.62 1.06 23 1.37 0.83 18 
4 1.76 0.66 24 1.94 1.05 22 1.43 0.54 15 
6 2.56 1.64 14 2.19 1.10 13 1.27 0.43 9 
8 2.22 0.77 5 1.48 0.41 5 0.98 0.08 3 
10 1.97 0.19 4 1.27 0.34 3 0.99 0.12 3 
Legend: X = mean SD = standard deviation n = number of patients evaluated 
Baseline = value prior to beginning heparin 

* 


























Base 2 4 6 8 10 
L i n e Days on Heparin 








Cfor standard deviation 
-i r~ 
4 6 
Days on Heparin 
~ r 
10 
and number of patients at each data point see Table 16B <-n 
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SERUM GLUTAMIC PYRUVIC TRANSAMINASE 
Correlation of Number of Days on Heparin to the Peak Enzyme 
Level While on Heparin. (Illustration 3) 












# Days on Heparin 
1 2 3 4 5 6 7 8 9 10 
n = 31 
X = 5.97 
Y = 5.52 
r = 0.881 
LEGEND 
Numbers in boxes represent numbers of patients peaking on that day 
(for example - 5 patients had their peak value on the 5th day while 
on 5 days of heparin therapy) 
X = mean number of days on heparin 
Y = mean number of days to peak enzyme level 
n = total number of patients evaluated 
* 
r = correlation coefficient 
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SERUM GLUTAMIC OXALOACETIC TRANSAMINASE 
Correlation of Number of Days on Heparin to the Peak Enzyme 
Level While on Heparin. (Illustration 4) 
# Days on Heparin 
+ 
1 2 3 4 5 6 7 8 9 10 












n = 31 
LEGEND 
X = 5.81 days 
Y = 4.42 days 
r = 0.586 
Numbers in boxes represent numbers of patients peaking on that day 
(for example - 6 patients had their peak value on the 4th day while 
on 4 days of heparin therapy) 
X = mean number of days on heparin 
Y = mean number of days to peak enzyme level 
n = total number of patients evaluated 
r = correlation coefficient 
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LACTIC DEHYDROGENASE 
Correlation of Number of Days on Heparin to the Peak Enzyme 
Level While on Heparin. (Illustration 5) 












# Days on Heparin 
1 2 3 4 5 6 7 8 9 10 
n = 23 
X = 5.5 
Y - 4.1 
r = 0.554 
LEGEND 
Numbers in boxes represent numbers of patients peaking on that day 
(for example - 2 patients had their peak value on the 3rd day while 
on 5 days of heparin therapy) 
X = mean number of days on heparin 
Y = mean number of days to peak enzyme level 
n = total number of patients evaluated 
r = correlation coefficient 
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